Skip to main content

Intermountain Precision Genomics and Myriad Genetics Now Offer Solid Tumor Testing in All 50 States

NYS Department of Health Clinical Laboratory Evaluation Program certifies Intermountain Precision Genomics Laboratory.

(PRUnderground) April 18th, 2023

Intermountain Precision Genomics and partner Myriad Genetics (NASDAQ: MYGN) are now certified to offer solid tumor testing to patients in all 50 U.S. states after receiving the New York State Clinical Laboratory Permit. This achievement follows a recent site inspection as part of the New York State Department of Health Clinical Laboratory Evaluation Program.

“This certification by the New York State Department of Health is a testament to this team’s dedication to laboratory safety and quality. The standard for this certification is high, and we’re proud to deliver on that,” said Jason Gillman, Precision Health Operations director, Intermountain Precision Genomics, a service of Intermountain Health. “Expanding into New York opens the door for Intermountain Precision Genomics and our partners at Myriad Genetics to serve many more patients and healthcare providers than before. We believe our cancer genomics services should be available to every late-stage cancer patient who needs it.”

Intermountain Precision Genomics’ TheraMap®: Solid Tumor genomic test, also offered by Myriad as Precise™ Tumor, analyzes a patient’s tumor DNA to discover what changes, or gene mutations, are causing the cancer. Specialists apply the results to recommend a targeted treatment plan for the patient’s unique tumor profile.

“The NYS certification represents an important step forward in the advancement of precision medicine by increasing access to genetic testing that can help patients with cancer and their providers determine more targeted treatment decisions,” said Michael Lyons, president of Oncology, Myriad Genetics. “Working in close collaboration with Intermountain Precision Genomics, we’re now able to offer the complete Precise Oncology Solutions suite in all 50 states.”

In 2021, Intermountain Health and Myriad announced a collaboration on a comprehensive offering of tests, which includes TheraMap/Precise Tumor. The suite, known as Preciseä Oncology Solutions, provides oncologists with a complete genetic analysis combining somatic tumor profiling, tissue analysis, and germline testing into one report – helping them establish individualized treatment options for each patient.

TheraMap is the first test in Intermountain Precision Genomics history to obtain this certification. Myriad Genetics was previously certified by the New York State Department of Health for its MyRisk® Hereditary Cancer test and somatic tumor profiling MyChoice® CDx test.

Visit for more information about TheraMap testing, or for more on Myriad’s Precise Oncology Solutions.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit

About Intermountain Health

Headquartered in Utah with locations in seven states and additional operations across the western U.S., is a nonprofit system of 33 hospitals, 385 clinics, medical groups with some 3,900 employed physicians and advanced care providers, a health plans division called SelectHealth with more than one million members, and other health services. Helping people live the healthiest lives possible, Intermountain is committed to improving community health and is widely recognized as a leader in transforming healthcare by using evidence-based best practices to consistently deliver high-quality outcomes at sustainable costs. For more information or updates, see

The post Intermountain Precision Genomics and Myriad Genetics Now Offer Solid Tumor Testing in All 50 States first appeared on PRUnderground.

Press Contact

Name: Brad Gillman
Phone: 385.275.8245
Email: Contact Us

Original Press Release.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.